CN EN

About Norroy

Our Technology

Nuclear Equipment

Press Release

Release News

Contact

Innovative radiopharmaceutical R&D

Enhanced radiopharmaceutical development dedicated to addressing treatment-resistant tumor domains, such as urological cancer and digestive tract tumors, that do not meet current clinical needs.
Focus on new and mature targets

Have a number of independent research and development pipelines of innovative drugs with global intellectual property rights.
Enhance the industry's capacity for innovation

Accelerating the delivery of more innovative treatments for patients.

Innovative Radiopharmaceutical Development

Dedicated to addressing the unmet clinical needs in the field of refractory tumors such as urinary and digestive tract tumors
Focus on new drugs and mature targets

A rich R&D pipeline with multiple independent research and development and innovative drugs with global intellectual property rights
Improve industry innovation capabilities

Accelerate to bring more innovative therapies to patients

Learn about Norroy

Focus on the full life cycle of nuclear medicine products

Founded in 2021, Norroy bioscience Co., Ltd. is a biomedical enterprise dedicated to pioneering research and innovative diagnosis and treatment in the field of radio pharmaceuticals. Norroy's focused approach on addressing unmet clinical needs in urinary system tumors and gastrointestinal tumors has driven a fast proof of concept and rapid commercialization of our two-wheeled strategy. This strategic development aligns with China's original layout research innovation in nuclear medicine, emphasizing excellence in both the First Class and Best in Class dimensions.

R＆D
Manufacturing
Quality Details

Balance innovation, speed, and steadiness.

Technology platform of clinical transformation

Norroy has an independent platform for proprietary technology. This platform integrates nuclear medicine technology, high-throughput screening,

MORE+

R&D and manufacturing base

The Wuxi base of Norroy is scheduled to be operational by 2023, encompassing a total construction area of approximately 3000 square meters.

MORE+

Our leadership

Norroy possesses a comprehensive expertise from drug discovery to commercialization of nuclear medicine, supported by a highly skilled and experienced professional team.

MORE+